LGALS9

LGALS9
Available structures
PDBHuman UniProt search: PDBe RCSB
Identifiers
Aliases LGALS9, HUAT, LGALS9A, galectin 9
External IDs HomoloGene: 32078 GeneCards: LGALS9
RNA expression pattern
More reference expression data
Orthologs
Species Human Mouse
Entrez

3965

n/a

Ensembl

ENSG00000168961

n/a

UniProt

O00182

n/a

RefSeq (mRNA)

NM_002308
NM_009587

n/a

RefSeq (protein)

NP_002299.2
NP_033665.1

n/a

Location (UCSC) Chr 17: 27.63 – 27.65 Mb n/a
PubMed search [1] n/a
Wikidata
View/Edit Human

Galectin-9 is a protein that in humans is encoded by the LGALS9 gene.[2][3]

The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. The protein encoded by this gene is an S-type lectin. This galectin is strongly overexpressed in Hodgkin's disease tissue and it might participate in the interaction between the H&RS cells with their surrounding cells and might thus play a role in the pathogenesis of this disease and/or its consistently associated immunodeficiency. The protein has N- and C- terminal carbohydrate-binding domains connected by a link peptide. Multiple alternatively spliced transcript variants have been found for this gene.[3]

References

  1. "Human PubMed Reference:".
  2. Tureci O, Schmitt H, Fadle N, Pfreundschuh M, Sahin U (Apr 1997). "Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease". J Biol Chem. 272 (10): 6416–22. doi:10.1074/jbc.272.10.6416. PMID 9045665.
  3. 1 2 "Entrez Gene: LGALS9 lectin, galactoside-binding, soluble, 9 (galectin 9)".

Further reading

  • Hirashima M, Kashio Y, Nishi N, et al. (2004). "Galectin-9 in physiological and pathological conditions". Glycoconj. J. 19 (7–9): 593–600. doi:10.1023/B:GLYC.0000014090.63206.2f. PMID 14758084. 
  • Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID 8125298. 
  • Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID 9373149. 
  • Matsumoto R, Matsumoto H, Seki M, et al. (1998). "Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes". J. Biol. Chem. 273 (27): 16976–84. doi:10.1074/jbc.273.27.16976. PMID 9642261. 
  • Matsumoto R, Hirashima M, Kita H, Gleich GJ (2002). "Biological activities of ecalectin: a novel eosinophil-activating factor". J. Immunol. 168 (4): 1961–7. doi:10.4049/jimmunol.168.4.1961. PMID 11823532. 
  • Kageshita T, Kashio Y, Yamauchi A, et al. (2002). "Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance". Int. J. Cancer. 99 (6): 809–16. doi:10.1002/ijc.10436. PMID 12115481. 
  • Imaizumi T, Kumagai M, Sasaki N, et al. (2002). "Interferon-gamma stimulates the expression of galectin-9 in cultured human endothelial cells". J. Leukoc. Biol. 72 (3): 486–91. PMID 12223516. 
  • Asakura H, Kashio Y, Nakamura K, et al. (2003). "Selective eosinophil adhesion to fibroblast via IFN-gamma-induced galectin-9". J. Immunol. 169 (10): 5912–8. doi:10.4049/jimmunol.169.10.5912. PMID 12421975. 
  • Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241Freely accessible. PMID 12477932. 
  • Kashio Y, Nakamura K, Abedin MJ, et al. (2003). "Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway". J. Immunol. 170 (7): 3631–6. doi:10.4049/jimmunol.170.7.3631. PMID 12646627. 
  • Abedin MJ, Kashio Y, Seki M, et al. (2003). "Potential roles of galectins in myeloid differentiation into three different lineages". J. Leukoc. Biol. 73 (5): 650–6. doi:10.1189/jlb.0402163. PMID 12714580. 
  • Matsuda A, Suzuki Y, Honda G, et al. (2003). "Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways". Oncogene. 22 (21): 3307–18. doi:10.1038/sj.onc.1206406. PMID 12761501. 
  • Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs". Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039. 
  • Irie A, Yamauchi A, Kontani K, et al. (2005). "Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer". Clin. Cancer Res. 11 (8): 2962–8. doi:10.1158/1078-0432.CCR-04-0861. PMID 15837748. 
  • Kasamatsu A, Uzawa K, Nakashima D, et al. (2005). "Galectin-9 as a regulator of cellular adhesion in human oral squamous cell carcinoma cell lines". Int. J. Mol. Med. 16 (2): 269–73. doi:10.3892/ijmm.16.2.269. PMID 16012760. 
  • Dai SY, Nakagawa R, Itoh A, et al. (2005). "Galectin-9 induces maturation of human monocyte-derived dendritic cells". J. Immunol. 175 (5): 2974–81. doi:10.4049/jimmunol.175.5.2974. PMID 16116184. 
  • Zhu C, Anderson AC, Schubart A, et al. (2006). "The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity". Nat. Immunol. 6 (12): 1245–52. doi:10.1038/ni1271. PMID 16286920. 
  • van de Weyer PS, Muehlfeit M, Klose C, et al. (2007). "A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9". Biochem. Biophys. Res. Commun. 351 (2): 571–6. doi:10.1016/j.bbrc.2006.10.079. PMID 17069754. 


This article is issued from Wikipedia - version of the 6/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.